ENSC
Ensysce Biosciences, Inc.
ENSC lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
ENSC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ENSC's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ENSC PE Valuation
ENSC has no meaningful PE right now: it lost money over the past year.
ENSC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect ENSC's losses to shrink, with revenue growing.
ENSC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.75 | +$8.47 |
| Q2 2026 | -$2.52 | +$9.36 |
| Q1 2026 | -$3.11 | +$11.28 |
| Q4 2025 | -$3.98 | +$17.27 |
| Q3 2025 | -$14.22 | +$7.68 |
| Q2 2025 | -$11.88 | +$24.12 |
| Q1 2025 | -$14.39 | +$33.01 |
| Q4 2024 | -$21.25 | +$49.10 |
ENSC lost $5.75 per share over the past year, a smaller loss than the year before.
ENSC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +342% |
| Q2 2026 | $1.2M | -15% |
| Q1 2026 | $961K | -27% |
| Q4 2025 | $1.9M | +44% |
| Q3 2025 | $493.1K | -86% |
| Q2 2025 | $1.4M | +654% |
| Q1 2025 | $1.3M | +332% |
| Q4 2024 | $1.3M | +153% |
ENSC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 342% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3781% | -3023 points |
| Q2 2026 | -221% | -94 points |
| Q1 2026 | -371% | -222 points |
| Q4 2025 | -148% | +127 points |
| Q3 2025 | -759% | -778 points |
| Q2 2025 | -128% | +948 points |
| Q1 2025 | -149% | +454 points |
| Q4 2024 | -274% | +338 points |
ENSC's operating margin was −3781% last quarter, down 3023 points from the same quarter a year ago, near the bottom of its range since 2021.
ENSC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$744.4K |
| Q1 2026 | -$3.5M | -$1.8M |
| Q4 2025 | -$1.5M | -$761.7K |
| Q2 2025 | -$2.7M | -$397K |
| Q1 2025 | -$1.7M | +$1.7M |
| Q4 2024 | -$764.1K | +$1M |
| Q3 2024 | -$1M | +$1.2M |
| Q2 2024 | -$2.3M | +$798.7K |
ENSC has burned cash in almost every quarter: −$8M over the past year, against −$6M the year before.
ENSC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +40% | +5.2M shares |
| 1 year | +530% | +15.3M shares |
| 3 years | +25787% | +18.1M shares |
| 5 years | +985979% | +18.2M shares |
| Available history | +1077056% | +18.2M shares |
ENSC has 18M diluted shares, up 530% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | $136.3M |
ENSC Net Leverage
ENSC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ENSC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 20.9 | Neutral |
ENSC's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
ENSC PE vs Healthcare Sector
| Metric | ENSC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ENSC has no meaningful PE right now: it lost money over the past year.
ENSC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 9.3% below |
| 20 week MA | $0.40 | 2.5% below |
| 50 week MA | $0.53 | 26% below |
| 100 week MA | $1.97 | 80% below |
| 200 week MA | $14.8 | 97% below |
ENSC is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
ENSC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37,224.0 | $47,808.0 | +28% |
| 2021 | $47,808.0 | $18,432.0 | -61% |
| 2022 | $18,432.0 | $129.6 | -99% |
| 2023 | $129.6 | $15.9 | -88% |
| 2024 | $15.9 | $8.88 | -44% |
| 2025 | $8.88 | $1.10 | -88% |
| 2026 YTD | $1.10 | $0.39 | -65% |
ENSC has finished five years in a row lower, and it's down 65% so far in 2026.